European Journal of Clinical Pharmacology

, Volume 30, Issue 2, pp 191–194 | Cite as

Fenofibrate and colestipol: Effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia

  • P. Weisweiler
  • W. Merk
  • B. Jacob
  • P. Schwandt


Effects on serum lipoproteins were studied in ten patients with familial hypercholesterolaemia (FH) during consecutive eight-week treatment periods with fenofibrate 0.3 g/day, fenofibrate plus colestipol, 15 g/day, and fenofibrate 0.25 g/day plus colestipol. VLDL, LDL, HDL, HDL2, and HDL3 were isolated by ultracentrifugation and precipitation. Lipids and apolipoproteins A–I and B were determined by enzymatic and immunonephelometric techniques, respectively. Administration of fenofibrate alone resulted in decreases in VLDL and LDL cholesterol (−48% and −18%) and in serum apolipoprotein B (−10%), but in increases in HDL, HDL2, and HDL3 (+25%, +26%, and +24%), and in serum apolipoprotein A–I (+6%). Addition of colestipol produced a further reduction in LDL cholesterol (−31%) and in serum apolipoprotein B (−19%). The effects were maintained with less fenofibrate. In FH, an acceptable therapy combines the favourable effects of sufficient lowering of LDL and of a rise in HDL.

Key words

colestipol fenofibrate familial hypercholesterolaemia lipoproteins serum lipids 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jensen J, Blankenhorn DH, Korneryp V (1967) Coronary disease in familial hypercholesterolemia. Circulation 36: 77–82Google Scholar
  2. 2.
    Witztum JL, Schonfeld G, Weidman SW (1976) The effects of colestipol on the metabolism of very low-density lipoproteins in man. J Lab Clin Med 88: 1008–1018Google Scholar
  3. 3.
    Shepherd J, Packard CJ, Bicker S, Lawrie TDV, Morgan HG (1980) Cholestyramine promotes receptor-mediated low-density lipoprotein catabolism. N Engl J Med 302: 1219–1222Google Scholar
  4. 4.
    Kane JP, Malloy MJ, Tun P, Phillips NR, Freedman DD, Williams ML, Rowe JS, Havel RJ (1981) Normalization of low-density lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen. N Engl J Med 304: 251–258Google Scholar
  5. 5.
    Rössner S, Orö L (1981) Fenofibrate therapy of hyperlipoproteinemia. A dose-response study and a comparison with clofibrate. Atherosclerosis 38: 273–282Google Scholar
  6. 6.
    Weisweiler P, Merk W, Janetschek P, Schwandt P (1984) Effect of fenofibrate on serum lipoproteins in subjects with familial hypercholesterolemia and combined hyperlipidemia. Atherosclerosis 53: 321–325Google Scholar
  7. 7.
    Hunninghake DB, Probstfield JL, Crow LO, Isaacson SO (1981) Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia. Metabolism 30: 605–609Google Scholar
  8. 8.
    Mabuchi H, Sakai T, Sakai Y, Yoshimura A, Watanabe A, Wakasugi T, Koizumi J, Takeda R (1983) Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N Engl J Med 308: 609–613Google Scholar
  9. 9.
    Nessim SA, Chin HP, Alaupovic P, Blankenhorn DH (1983) Combined therapy of niacin, colestipol, and fat-controlled diet in men with coronary bypass. Effect on blood lipids and apolipoproteins. Arteriosclerosis 3: 568–573Google Scholar
  10. 10.
    Jackson JM, Lee H (1984) The effect of probucol and cholestyramine combination therapy in severe familial hypercholesterolaemia. Atherosclerosis 51: 189–197Google Scholar
  11. 11.
    Motulsky AG (1976) The genetic hyperlipidemias. N Engl J Med 294: 823–827Google Scholar
  12. 12.
    Havel RJ, Eder HA, Bragdon JH (1985) The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345–1353Google Scholar
  13. 13.
    Warnick GR, Nguyen T, Albers AA (1985) Comparison of improved precipitation methods for quantification of high-density lipoprotein cholesterol. Clin Chem 31: 217–222Google Scholar
  14. 14.
    Weisweiler P, Schwandt P (1981) Effects of etiroxate on low-density and high-density lipoproteins in hypercholesterolemic patients. Atherosclerosis 39: 45–49Google Scholar
  15. 15.
    Weisweiler P, Schwandt P, Friedl C (1984) Determination of human apolipoproteins A–I, B, and E by laser nephelometry. J Clin Chem Clin Biochem 22: 113–118Google Scholar
  16. 16.
    Wissenschaftliche Tabellen Geigy, Teilband Statistik. Ciba-Geigy, Basel, 1980Google Scholar
  17. 17.
    Lipid Research Clinics Program (1984) The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. J Am Med Ass 251: 351–364Google Scholar
  18. 18.
    Angelin BB, Einarsson K (1981) Cholestyramine in type IIa hyperlipoproteinemia. Is low-dose treatment feasable? Atherosclerosis 38: 33–38Google Scholar
  19. 19.
    Schlierf G, Mrozik K, Heuck C, Middelhoff G, Oster P, Riesen W, Schellenberg B (1982) ‘Low dose’ colestipol in children, adolescents and young adults with familial hypercholesterolemia. Atherosclerosis 41: 133–138Google Scholar
  20. 20.
    Shepherd J, Caslake MJ, Lorimer AR, Vallance BD, Packard CJ (1985) Fenofibrate reduces low-density lipoprotein catabolism in hypertriglyceridemic subjects. Arteriosclerosis 5: 162–168Google Scholar
  21. 21.
    Stewart JM, Packard CJ, Loriner AR, Boag DE, Shepherd J (1982) Effects of bezafibrate on receptor-mediated and receptor-independent low-density lipoprotein catabolism in type II hyperlipoproteinemic subjects. Atherosclerosis 44: 355–365Google Scholar
  22. 22.
    Shepherd J, Packard CJ (1984) Mode of action of lipid-lowering drugs. In: Miller NE (ed) Atherosclerosis: Mechanisms and approaches to therapy. Raven Press, New York, pp 169–202Google Scholar
  23. 23.
    Chao YS, Yamin TT, Alberts AW (1982) Catabolism of low-density lipoproteins by perfused rabbit livers: cholestyramine promotes recepter-dependent hepatic catabolism of low-density lipoproteins. Proc Natl Acad Sci USA 79: 3983–3986Google Scholar
  24. 24.
    Witztum JL, Young SG, Elam RL, Carew TE, Fisher M (1985) Cholestyramine-induced changes in low density lipoprotein composition and metabolism. I. Studies in the guinea pig. J Lipid Res 26: 92–103Google Scholar
  25. 25.
    Cheung MC, Albers JJ, Wahl PW, Hazzard WR (1980) High-density lipoproteins during hyperlipidemic therapy. A comparative study of four drugs. Atherosclerosis 35: 215–228Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • P. Weisweiler
    • 1
  • W. Merk
    • 1
  • B. Jacob
    • 1
  • P. Schwandt
    • 1
  1. 1.Medical Department II, Grosshadern ClinicUniversity of MunichMunichGermany

Personalised recommendations